Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 11/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.37 |
| ▸ | PRKACA | P17612 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806346 | 1.00 | CDC7 (0.43) | CDC7PDE3BPDE3AROCK2CLK4 | |
| SCHEMBL861165 | 0.87 | HDAC2 (0.37) | ROCK2CLK4PRKACAGSK3BDYRK1B | |
| SCHEMBL2599139 | 0.87 | HDAC2 (0.37) | ROCK2CLK4PRKACAGSK3BDYRK1B | |
| SCHEMBL861164 | 0.87 | HDAC2 (0.37) | ROCK2CLK4PRKACAGSK3BDYRK1B | |
| Hydrochloric Acid SCHEMBL20575422 | 0.86 | HDAC2 (0.37) | ROCK2CLK4PRKACAGSK3BDYRK1B | |
| Hydrochloric Acid SCHEMBL1805154 | 0.86 | HDAC2 (0.37) | ROCK2CLK4PRKACAGSK3BDYRK1B | |
| Hydrochloric Acid SCHEMBL1805772 | 0.86 | HDAC2 (0.37) | ROCK2CLK4PRKACAGSK3BDYRK1B | |
| SCHEMBL861528 | 0.84 | PTPRC (0.40) | CDC7CDK2GSK3BMAPKAPK2GSK3A | |
| SCHEMBL861529 | 0.84 | PTPRC (0.40) | CDC7CDK2GSK3BMAPKAPK2GSK3A | |
| SCHEMBL861058 | 0.82 | HTR2C (0.37) | PDE3BPDE3ACHRNB2CHRNA4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | claimed |
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2016-04-07 | — | — | US | claimed |
| US-9187483-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2015-11-17 | — | — | US | claimed |
| EP-2641907-B1 | Preparation of modulators of 5-HT receptors | ABBVIE INC (US) | 2015-01-28 | — | — | EP | claimed |
| EP-2641907-A1 | Preparation of modulators of 5-HT receptors | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2432783-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2013-05-01 | — | — | EP | claimed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | claimed |
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | disclosed |
| US-9879033-B2 | Modulators of 5-HT receptors and methods of use thereof | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-30 | — | — | US | disclosed |
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2016-04-07 | — | — | US | disclosed |
| US-9187483-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2641907-B1 | Preparation of modulators of 5-HT receptors | ABBVIE INC (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2641907-A1 | Preparation of modulators of 5-HT receptors | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2432783-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CDC7 3719/4885PDE3B 417/4885PDE3A 306/4885 |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CDC7 3719/4885PDE3B 417/4885PDE3A 306/4885 |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CDC7 3719/4885PDE3B 417/4885PDE3A 306/4885 |
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CDC7 3719/4885PDE3B 417/4885PDE3A 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.